Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02051738 | A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants | PHASE1 | COMPLETED | 1 | — | — | Feb 1, 2014 | Apr 1, 2014 | Jun 27, 2014 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence AB | EXPERIMENTAL | A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B). |
| Treatment Sequence BA | EXPERIMENTAL | A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A). |
| Name | Type | Description |
|---|---|---|
| Mebendazole - fasted state (Treatment A) | DRUG | Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition. |
| Mebendazole - fed state (Treatment B) | DRUG | Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition. |
Inclusion Criteria: * Must have signed an informed consent document * Woman must be postmenopausal, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry and throughout the study * Woman must have a negative serum human chorionic gona...